2019 Archives

Following backlash, Facebook disables misleading HIV medication ads

Dec. 30, 2019, 3:44 PM EST

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid Initiation Model of Care for HIV-1 Infection: Primary Analysis of the DIAMOND Study

Clinical Infectious Diseases 27 December 2019

What's New in the Guidelines?

aidsinfo | December 2019

ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

ViiV Healthcare | December 21, 2019

Prescribing practices for pregnant women with HIV not aligned with guidelines 

Healio | December 18, 2019

Facebook ads are spreading lies about anti-HIV drug PrEP. The company won't act 

The Guardian | December 14, 2019

Cost prevents 7% of people will HIV from adhering to medication 

Healio | December 12, 2019

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Viiv | December 5, 2019

HARVONI, EPCLUSA, and VOSEVI Labeling updates: HCV-infected adults with severe renal impairment

FDA | November 18, 2019

CDC Antibiotic Resistance: New Threats Report

Understanding the Medicaid Prescription Drug Rebate Program – Kaiser Family Foundation

KFF | November 12, 2019

Untangling the Trump administration's lawsuit over an HIV prevention drug 

Science Magazine | November 8, 2019

Facts About Gilead’s PrEP Medications Donation to Help Support Ending the HIV Epidemic Efforts

NATAP | November 4, 2019 at 12:01:02 PM EST

Gilead Perspective on HHS Lawsuit

The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC+DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV

17th European AIDS Conference, November 6-9, 2019, Basel

Integrase Inhibitors Tied to Weight Gain, Hepatic Steatosis in Longitudinal Cohort

17th European AIDS Conference, November 6-9, 2019, Basel

INI Resistance Remains Rare in INI-Naive--Initial CD4, Viral Load Predict Failure

17th European AIDS Conference, November 6-9, 2019, Basel

Switch From TDF to TAF in HIV/HBV+ Maintains Viral Control, Helps Kidneys

17th European AIDS Conference, November 6-9, 2019, Basel

DTG Easily Most Popular INI Across Europe, With Lowest Quitting Rate

17th European AIDS Conference, November 6-9, 2019, Basel

Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy

Gilead | November 8, 2019

BARACLUDE: Updates to Adverse Reactions from Long-Term Observational Study

FDA | November 8, 2019

Label updates to efavirenz containing products

FDA | October 30, 2019

Hepatitis C Treatments Are Safe and Effective for Seniors

POZ | October 28, 2019

Dolutegravir and risk of neural tube defects: Labeling Updates

FDA | October 25, 2019

Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work

The Body Pro | October 16, 2019

Rapid ART Initiation: A New Model Presents Unique Opportunities and Challenges 

Contagionlive.com | October 11, 2019

The 8th World Workshop on Oral Health and Disease in AIDS

BRITISH DENTAL JOURNAL | VOLUME 227 NO. 7 | October 11 2019

Photos courtesy of Dr. David Croser

IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

ViiV Healthcare | October 2, 2019

MAVYRET: new dosage regimen and labeling updates

FDA | October 1, 2019

FDA approves new HIV treatment (Long-Acting Ibalizumab) for patients who have limited treatment options

NATAP | September 26, 2019

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

Business Wire | September 20, 2019

Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV

Yahoo Finance | September 19, 2019

FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease

FDA | August 28, 2019

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

GSK | August 22, 2019

Extensive Drug Resistance Has Become Rare Among People With HIV

POZ | August 19, 2019

FDA panel backs Gilead's HIV prevention drug for certain population

Reuters | August 7, 2019

BIKTARVY: recent changes to labeling

FDA | August 6, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational ... 

Yahoo Finance | July 29, 2019

WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For ... 

Kaiser Family Foundation | July 23, 2019

Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir

EurekAlert | July 23, 2019

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

The Lancet | July 12, 2019

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 

aidsinfo | July 10, 2019

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

BioSpace | July 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

ViiV Healthcare | July 10, 2019

GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen 

Reuters | July 10, 2019

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

BioSpace | July 9, 2019

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

ViiV Healthcare | July 8, 2019

TRUVADA: Important Updates to the REMS

FDA: HIV Email Updates | July 1, 2019

Long-Acting Antiretrovirals for Treatment 

NASTAD | June 26, 2019

HIV Updates: BIKTARVY label revisions

HIV drug cabotegravir not associated with weight gain

Healio | June 8, 2019

AIDS groups criticize Express Scripts for excluding several HIV medicines

STAT | June 6, 2019

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2019 Annual Report

NASTAD | June 6, 2019

Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Baseline genotype testing at HIV diagnosis not cost-effective

Healio | May 13, 2019

Gilead to Donate Up to 2.4M Bottles of HIV Prevention Pills Each Year in the U.S.

POZ | May 10, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

NIH | May 9, 2019

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet | May 5, 2019

ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment

WRAL Tech Wire | April 29, 2019

MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication

AIDS Behav. 2018 Apr;22(4):1158-1164. doi: 10.1007/s10461-017-1972-6

Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591

NATAP | April 10, 2019

NATAP: HIV-Drug Resistance Testing/DHHS Guidelines

Last Updated: October 25, 2018

ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection

ViiV | April 26, 2019

New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds

POZ | April 23, 2019

Special thanks to The AIDS Institute for leading the charge on this important issue

Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

NATAP | April 18, 2019

FDA Has Approved New Two-Drug Regimen to Treat People with HIV

Healthline | April 15, 2019

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

Janssen | April 11, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA | April 8, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Market Watch |  Apr 9, 2019

Pharma giant profits from HIV treatment funded by taxpayers and patented by the government

Washington Post | March 26, 2019

Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

Gilead | March 26, 2019

Long-acting injectable treatment maintains viral suppression

aidsmap | March 8, 2019

Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable

Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle

Integrase inhibitor treatment leads to greater weight gain

aidsmap | March 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

ViiV | March 7, 2019

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead | February 11, 2019

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

NIH | February 8, 2019

FDA Hepatitis Update- VEMLIDY labeling revised (renal information)

FDA | February 6, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019